1 INTRODUCTION
1.1 MARKET SEGMENTATION
2 RESEARCH METHODOLOGY
2.1 ECOSYSTEM OF RHEUMATOLOGY THERAPEUTICS MARKET
2.2 TOP-DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SNAPSHOT
3.2 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET REVENUE, 2017– 2025(US$ MN)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 KEY TRENDS ANALYSIS
4.3 PRODUCT DEVELOPMENT AND DIVERSIFICATION ANALYSIS
4.4 PORTERS FIVE FORCE ANALYSIS
4.5 VALUE CHAIN ANALYSIS
4.6 COMPETITIVE LANDSCAPE
4.7 COMPANY MARKET SHARE ANALYSIS
4.8 EXPANSION STRATEGIES ADOPTED BY LEADING PLAYERS
5 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, BY DRUG TYPES
5.1 OVERVIEW
5.2 DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
5.3 CORTICOSTEROIDS
5.4 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
5.5 IMMUNOSUPPRESSANT DRUGS
5.6 BIOLOGICS
6 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, BY DISEASE TYPE
6.1 OVERVIEW
6.2 RHEUMATOID ARTHRITIS
6.3 GOUT
6.4 OSTEOARTHRITIS
6.5 JUVENILE IDIOPATHIC ARTHRITIS
6.6 SCLERODERMA
6.7 SJOGREN’S SYNDROME
6.8 OTHERS
7 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, BY  METHOD OF ADMINISTRATION
7.1 OVERVIEW
7.2 TOPICAL
7.3 ORAL
7.4 PARENTERAL
8 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
8.1 HOSPITAL
8.2 ONLINE
8.3 RETAIL
8.4 OTHERS
9 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, BY GEOGRAPHY
9.1 NORTH AMERICA
9.1.1 MARKET DYNAMICS
9.1.1.1 DRIVERS
9.1.1.2 RESTRAINS
9.1.1.3 OPPORTUNITY
9.1.2 U.S.
9.1.3 CANADA
9.1.4 MEXICO
9.2 EUROPE
9.2.1 MARKET DYNAMICS
9.2.1.1 DRIVERS
9.2.1.2 RESTRAINS
9.2.1.3 OPPORTUNITY
9.2.2 U.K.
9.2.3 FRANCE
9.2.4 GERMANY
9.2.5 SPAIN
9.2.6 REST OF EUROPE
9.3 ASIA PACIFIC
9.3.1 MARKET DYNAMICS
9.3.1.1 DRIVERS
9.3.1.2 RESTRAINS
9.3.1.3 OPPORTUNITY
9.3.2 INDIA
9.3.3 CHINA
9.3.4 JAPAN
9.3.5 REST OF ASIA PACIFIC
9.4 MIDDLE EAST AND AFRICA
9.4.1 MARKET DYNAMICS
9.4.1.1 DRIVERS
9.4.1.2 RESTRAINS
9.4.1.3 OPPORTUNITY
9.4.2 SOUTH AFRICA
9.4.3 REST OF MIDDLE EAST AND AFRICA
9.5 LATIN AMERICA
9.5.1 MARKET DYNAMICS
9.5.1.1 DRIVERS
9.5.1.2 RESTRAINS
9.5.1.3 OPPORTUNITY
9.5.2 BRAZIL
9.5.3 REST OF LATIN AMERICA
10 GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, BY COMPANY
10.1 INTRODUCTION
10.2 SANOFI S.A.
10.2.1 BUSINESS OVERVIEW
10.2.2 PRODUCTS & SERVICES
10.2.3 KEY STRATEGY
10.2.4 RECENT DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.3 TAKEDA PHARMACEUTICAL
10.3.1 BUSINESS OVERVIEW
10.3.2 PRODUCTS & SERVICES
10.3.3 KEY STRATEGY
10.3.4 RECENT DEVELOPMENTS
10.3.5 SWOT ANALYSIS
10.4 ABBVIE INC.
10.4.1 BUSINESS OVERVIEW
10.4.2 PRODUCTS & SERVICES
10.4.3 KEY STRATEGY
10.4.4 RECENT DEVELOPMENTS
10.4.5 SWOT ANALYSIS
10.5  REGENERON PHARMACEUTICALS INC.
10.5.1 BUSINESS OVERVIEW
10.5.2 PRODUCTS & SERVICES
10.5.3 KEY STRATEGY
10.5.4 RECENT DEVELOPMENTS
10.5.5 SWOT ANALYSIS
10.6 NOVARTIS AG
10.6.1 BUSINESS OVERVIEW
10.6.2 PRODUCTS & SERVICES
10.6.3 KEY STRATEGY
10.6.4 RECENT DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.7  AMGEN INC.
10.7.1 BUSINESS OVERVIEW
10.7.2 PRODUCTS & SERVICES
10.7.3 KEY STRATEGY
10.7.4 RECENT DEVELOPMENTS
10.7.5 SWOT ANALYSIS
10.8 JANSSEN BIOTECH INC.
10.8.1 BUSINESS OVERVIEW
10.8.2 PRODUCTS & SERVICES
10.8.3 KEY STRATEGY
10.8.4 RECENT DEVELOPMENTS
10.8.5 SWOT ANALYSIS
10.9 PFIZER INC.
10.9.1 BUSINESS OVERVIEW
10.9.2 PRODUCTS & SERVICES
10.9.3 KEY STRATEGY
10.9.4 RECENT DEVELOPMENTS
10.9.5 SWOT ANALYSIS
10.10 BRISTOL-MYERS SQUIBB COMPANY
10.10.1 BUSINESS OVERVIEW
10.10.2 PRODUCTS & SERVICES
10.10.3 KEY STRATEGY
10.10.4 RECENT DEVELOPMENTS
10.10.5 SWOT ANALYSIS